Irritable bowel syndrome and ischemic colitis: evidence supporting the increased use of alosetron.
作者信息
Lucak Susan
机构信息
Division of Digestive and Liver Diseases, Department of Medicine, Columbia University, 121 East 69th Street, New York, NY 10021, USA.
出版信息
Therap Adv Gastroenterol. 2012 Jul;5(4):215-8. doi: 10.1177/1756283X12450934.
Abstract
摘要
相似文献
1
Irritable bowel syndrome and ischemic colitis: evidence supporting the increased use of alosetron.肠易激综合征与缺血性结肠炎：支持增加使用阿洛司琼的证据
Therap Adv Gastroenterol. 2012 Jul;5(4):215-8. doi: 10.1177/1756283X12450934.
2
Optimizing outcomes with alosetron hydrochloride in severe diarrhea-predominant irritable bowel syndrome.盐酸阿洛司琼在以腹泻为主的严重肠易激综合征中的优化效果。
Therap Adv Gastroenterol. 2010 May;3(3):165-72. doi: 10.1177/1756283X10362277.
3
Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials.阿洛司琼治疗女性和男性肠易激综合征的疗效及耐受性：八项随机、安慰剂对照、为期12周试验的荟萃分析
Clin Ther. 2008 May;30(5):884-901. doi: 10.1016/j.clinthera.2008.05.002.
4
Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data.使用阿洛司琼的患者中缺血性结肠炎的发病率及便秘的严重并发症：对临床试验和上市后监测数据的系统评价
Am J Gastroenterol. 2006 May;101(5):1069-79. doi: 10.1111/j.1572-0241.2006.00459.x.
5
Alosetron, a 5-HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers.阿洛司琼，一种5-羟色胺3受体拮抗剂，可延缓肠易激综合征患者和健康志愿者的结肠转运。
Aliment Pharmacol Ther. 2000 Jun;14(6):775-82. doi: 10.1046/j.1365-2036.2000.00762.x.
6
Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspective.阿洛司琼治疗以腹泻为主的严重肠易激综合征：安全性和疗效透视。
Expert Rev Gastroenterol Hepatol. 2010 Feb;4(1):13-29. doi: 10.1586/egh.09.72.
7
Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: analysis of two controlled trials.阿洛司琼对重度腹泻型肠易激综合征女性肠道急迫感及整体症状的影响：两项对照试验的分析
Clin Gastroenterol Hepatol. 2004 Aug;2(8):675-82. doi: 10.1016/s1542-3565(04)00284-8.
8
Ischemic colitis during treatment with alosetron.使用阿洛司琼治疗期间发生的缺血性结肠炎。
Gastroenterology. 2001 Feb;120(2):557-60. doi: 10.1053/gast.2001.21177.
9
Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome.阿洛司琼对肠易激综合征患者结肠扩张反应的影响。
Aliment Pharmacol Ther. 1998 Sep;12(9):849-55. doi: 10.1046/j.1365-2036.1998.00375.x.
10
Ischemic colitis and complications of constipation associated with the use of alosetron under a risk management plan: clinical characteristics, outcomes, and incidences.缺血性结肠炎及与风险管理计划下使用阿洛司琼相关的便秘并发症：临床特征、结局和发生率。
Am J Gastroenterol. 2010 Apr;105(4):866-75. doi: 10.1038/ajg.2010.25. Epub 2010 Mar 2.
引用本文的文献
1
A case report of transmural rectosigmoid ischemia in an elderly patient.一位老年患者透壁性直肠乙状结肠缺血的病例报告。
Int J Surg Case Rep. 2023 Jun;107:108372. doi: 10.1016/j.ijscr.2023.108372. Epub 2023 May 30.
2
Update on Pharmacotherapy for Irritable Bowel Syndrome.肠易激综合征药物治疗的最新进展
Curr Gastroenterol Rep. 2019 Apr 25;21(6):25. doi: 10.1007/s11894-019-0692-7.
本文引用的文献
1
Evaluation of harm in the pharmacotherapy of irritable bowel syndrome.评估肠易激综合征药物治疗的危害。
Am J Med. 2012 Apr;125(4):381-93. doi: 10.1016/j.amjmed.2011.08.026.
2
Evaluation of treatment continuation with alosetron by IBS-D severity criteria.根据 IBS-D 严重程度标准评估阿洛司琼的治疗持续时间。
Curr Med Res Opin. 2012 Mar;28(3):449-56. doi: 10.1185/03007995.2011.653435. Epub 2012 Feb 7.
3
The risk of ischaemic colitis in irritable bowel syndrome patients treated with serotonergic therapies.肠易激综合征患者接受 5-羟色胺能治疗后发生缺血性结肠炎的风险。
Drug Saf. 2011 Jul 1;34(7):545-65. doi: 10.2165/11590690-000000000-00000.
4
Ischemic colitis and complications of constipation associated with the use of alosetron under a risk management plan: clinical characteristics, outcomes, and incidences.缺血性结肠炎及与风险管理计划下使用阿洛司琼相关的便秘并发症：临床特征、结局和发生率。
Am J Gastroenterol. 2010 Apr;105(4):866-75. doi: 10.1038/ajg.2010.25. Epub 2010 Mar 2.
5
Clinical trial: renzapride treatment of women with irritable bowel syndrome and constipation - a double-blind, randomized, placebo-controlled, study.临床试验：雷扎必利治疗伴有便秘的肠易激综合征女性患者 - 一项双盲、随机、安慰剂对照研究。
Aliment Pharmacol Ther. 2010 May;31(9):979-90. doi: 10.1111/j.1365-2036.2010.04265.x. Epub 2010 Feb 16.
6
Diseases and drugs that increase risk of acute large bowel ischemia.可导致急性大肠缺血风险增加的疾病和药物。
Clin Gastroenterol Hepatol. 2010 Jan;8(1):49-54. doi: 10.1016/j.cgh.2009.09.006. Epub 2009 Sep 16.
7
Epidemiology, clinical features, high-risk factors, and outcome of acute large bowel ischemia.急性大肠缺血的流行病学、临床特征、高危因素及预后
Clin Gastroenterol Hepatol. 2009 Oct;7(10):1075-80.e1-2; quiz 1023. doi: 10.1016/j.cgh.2009.05.026. Epub 2009 Jun 23.
8
Irritable bowel syndrome is more frequent in patients hospitalized for ischaemic colitis: results of a case-control study.缺血性结肠炎住院患者中肠易激综合征更为常见：一项病例对照研究的结果
Neurogastroenterol Motil. 2009 Nov;21(11):1170-e102. doi: 10.1111/j.1365-2982.2009.01333.x. Epub 2009 May 21.
9
International survey of patients with IBS: symptom features and their severity, health status, treatments, and risk taking to achieve clinical benefit.肠易激综合征患者的国际调查：症状特征及其严重程度、健康状况、治疗方法以及为实现临床获益所承担的风险。
J Clin Gastroenterol. 2009 Jul;43(6):541-50. doi: 10.1097/MCG.0b013e318189a7f9.
10
Ischemic colitis: clinical practice in diagnosis and treatment.缺血性结肠炎：诊断与治疗的临床实践
World J Gastroenterol. 2008 Dec 28;14(48):7302-8. doi: 10.3748/wjg.14.7302.
Zotero 插件